Efficacy of acupoint application in patients with overactive bladder: A randomized, placebo-controlled pilot trial

被引:0
作者
Tang, Heshu [1 ]
Zhu, Chunqin [2 ]
Xu, Suping [1 ]
Wang, Yan [1 ]
Gao, Juanjuan [1 ]
Zhou, Ping [1 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Neurol, 155 Hanzhong Rd, Nanjing 210029, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Nursing, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China
关键词
Overactive bladder; Acupoint application; Traditional Chinese medicine; OABSS; NGF; NERVE GROWTH-FACTOR; QUALITY-OF-LIFE; SYMPTOM; WOMEN;
D O I
10.1016/j.explore.2023.03.009
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Conventional treatments for alleviating the symptoms of Overactive bladder (OAB) have been reported to have limited efficacy and a high rate of side effects. Traditional Chinese medicine (TCM) has been used in Asia countries because of its low side effects and being easy to operate. To confirm the efficacy of acupoint application treatment for alleviating OAB symptoms, a randomized and placebo-controlled pilot trial was conducted in this study.Methods: All participants were randomly allocated into a treatment group or control group, receiving either a "Dinggui" acupoint application or placebo treatment for 4 weeks. The outcome measures were OAB symptom scores (OABSS), OAB questionnaire (OAB-q) scores, and TCM syndrome scores. Urine nerve growth factor (NGF) level, NGF normalized to urine creatinine (NGF/Cr), and maximum flow rate (Qmax) were also measured to evaluate the OAB symptoms. Results: In total, 69 participants were included with 34 in the treatment group and 35 in the placebo-treated group. Treatment with "Dinggui" acupoint application showed a statistically significant decrease in OABSS scores (8.10 & PLUSMN;1.54 to 3.67 & PLUSMN;1.77), OAB-q scores (61.43 & PLUSMN;13.93 to 38.13 & PLUSMN;15.42), and TCM syndrome scores (15.60 & PLUSMN;5.98 to 9.20 & PLUSMN;4.82). The NGF and NGF/Cr were also observed meaningful changes in a decrease from 379.68 to 136.17 pg/ml and from 0.30 to 0.16 pg/mg, respectively. The Qmax value showed a significant increase from 14.40 to 24.05 ml/s.Conclusions: Treatment with "Dinggui" acupoint application could be considered an effective and alternative therapy for OAB management. Further studies with larger sample sizes and longer treatment periods are needed to investigate.
引用
收藏
页码:749 / 754
页数:6
相关论文
共 50 条
  • [21] Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial
    Yamaguchi, Osamu
    Uchida, Eiji
    Higo, Naruhito
    Minami, Hidenao
    Kobayashi, Shigeo
    Sato, Hiroyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (06) : 586 - 593
  • [22] Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study)
    Otsuka, Atsushi
    Kageyama, Shinji
    Suzuki, Takahisa
    Matsumoto, Rikiya
    Nagae, Hiroshi
    Kitagawa, Motoaki
    Furuse, Hiroshi
    Ozono, Seiichiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (12) : 1016 - 1023
  • [23] OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
    Nitti, Victor W.
    Dmochowski, Roger
    Herschorn, Sender
    Sand, Peter
    Thompson, Catherine
    Nardo, Christopher
    Yan, Xiaohong
    Haag-Molkenteller, Cornelia
    JOURNAL OF UROLOGY, 2013, 189 (06) : 2186 - 2193
  • [24] A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients
    Welk, Blayne
    McKibbon, Mary
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (07): : E297 - E303
  • [25] Evaluation of an experimental urodynamic platform to identify treatment effects: A randomized, placebo-controlled, crossover study in patients with overactive bladder
    Frenkl, Tara
    Railkar, Radha
    Shore, Neal
    Bailen, James
    Sutherland, Suzette
    Burke, Joanne
    Scott, Boyd B.
    Ruddy, Marcella
    Beals, Chan
    NEUROUROLOGY AND URODYNAMICS, 2012, 31 (01) : 69 - 74
  • [26] Microablative radiofrequency versus sham for overactive bladder: a randomized controlled trial
    Slongo, Helena
    Lunardi, Anna Lygia B.
    Fazzolari, Juliana C.
    Perez, Constanza D. A.
    Riccetto, Cassio L. Z.
    Juliato, Cassia R. T.
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2025, 32 (03): : 191 - 196
  • [27] A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome
    Robinson, Dudley
    Cardozo, Linda
    Terpstra, Gerben
    Bolodeoku, John
    BJU INTERNATIONAL, 2007, 100 (04) : 840 - 845
  • [28] Acupuncture for cancer-related fatigue in lung cancer patients: a randomized, double blind, placebo-controlled pilot trial
    Cheng, Chien-shan
    Chen, Lian-yu
    Ning, Zhou-yu
    Zhang, Chen-yue
    Chen, Hao
    Chen, Zhen
    Zhu, Xiao-yan
    Xie, Jing
    SUPPORTIVE CARE IN CANCER, 2017, 25 (12) : 3807 - 3814
  • [29] The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial
    Moussa, Mohamad
    Abou Chakra, Mohamad
    Dabboucy, Baraa
    Fares, Youssef
    Dellis, Athanasios
    Papatsoris, Athanasios
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (01) : 66 - 72
  • [30] Use of Fermented Red Clover Isoflavones in the Treatment of Overactive Bladder in Postmenopausal Women: A Randomized, Double-Blinded, Placebo-Controlled Trial
    Villadsen, Annemarie B.
    Holm-Jacobsen, Julie N.
    Prabhala, Bala K.
    Bundgaard-Nielsen, Caspar
    Huntjens, Pam
    Kornum, Jette B.
    Glavind, Karin
    Leutscher, Peter D. C.
    Christensen, Lars P.
    Jeppesen, Per B.
    Sorensen, Suzette
    Arenholt, Louise T. S.
    NUTRIENTS, 2023, 15 (19)